MiR-15a and MiR-24-1 As Putative Prognostic MicroRNA Signatures for Pediatric Pilocytic Astrocytomas and Ependymomas

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Jan 28

PMID 26813564

Citations 17

Authors

M Braoudaki

G I Lambrou

K Giannikou

S A Papadodima

A Lykoudi

K Stefanaki

G Sfakianos

A Kolialexi

F Tzortzatou-Stathopoulou

M Tzetis

S Kitsiou-Tzeli

E Kanavakis

Affiliations

Soon will be listed here.

Abstract

In the current setting, we attempted to verify and validate miRNA candidates relevant to pediatric primary brain tumor progression and outcome, in order to provide data regarding the identification of novel prognostic biomarkers. Overall, 26 resected brain tumors were studied from children diagnosed with pilocytic astrocytomas (PAs) (n = 19) and ependymomas (EPs) (n = 7). As controls, deceased children who underwent autopsy and were not present with any brain malignancy were used. The experimental approach included microarrays covering 1211 miRNAs. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the expression profiles of miR-15a and miR-24-1. The multiparameter analyses were performed with MATLAB. Matching differentially expressed miRNAs were detected in both PAs and EPs, following distinct comparisons with the control cohort; however, in several cases, they exhibited tissue-specific expression profiles. On correlations between miRNA expression and EP progression or outcome, miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases when compared to EP clinical remission cases and EP survivors, respectively. Taken together, following several distinct associations between miRNA expression and diverse clinical parameters, the current study repeatedly highlighted miR-15a and miR-24-1 as candidate oncogenic molecules associated with inferior prognosis in children diagnosed with ependymoma.

Citing Articles

Nanoparticles for Drug and Gene Delivery in Pediatric Brain Tumors' Cancer Stem Cells: Current Knowledge and Future Perspectives.

Abballe L, Spinello Z, Antonacci C, Coppola L, Miele E, Catanzaro G Pharmaceutics. 2023; 15(2).

PMID: 36839827 PMC: 9962005. DOI: 10.3390/pharmaceutics15020505.

Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Dayakar A, Shanmukha K, Kalangi S Mol Biol Rep. 2022; 49(7):6827-6846.

PMID: 35031927 DOI: 10.1007/s11033-021-07040-2.

Differential and Common Signatures of miRNA Expression and Methylation in Childhood Central Nervous System Malignancies: An Experimental and Computational Approach.

Lambrou G, Poulou M, Giannikou K, Themistocleous M, Zaravinos A, Braoudaki M Cancers (Basel). 2021; 13(21).

PMID: 34771655 PMC: 8583574. DOI: 10.3390/cancers13215491.

Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications.

Chen S, Deng X, Sheng H, Rong Y, Zheng Y, Zhang Y Mol Ther Nucleic Acids. 2021; 26:417-431.

PMID: 34552822 PMC: 8426460. DOI: 10.1016/j.omtn.2021.07.024.

Co-Deregulated miRNA Signatures in Childhood Central Nervous System Tumors: In Search for Common Tumor miRNA-Related Mechanics.

Lambrou G, Zaravinos A, Braoudaki M Cancers (Basel). 2021; 13(12).

PMID: 34204289 PMC: 8235499. DOI: 10.3390/cancers13123028.

References

Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F . Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015; 37(4):560-8. DOI: 10.1111/ijlh.12351. View

Tian X, Zhang J, Yan L, Dong J, Guo Q . MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp Pathol. 2015; 8(6):6442-9. PMC: 4525854. View

Tafsiri E, Darbouy M, Shadmehr M, Zagryazhskaya A, Alizadeh J, Karimipoor M . Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumour Biol. 2014; 36(3):1603-12. DOI: 10.1007/s13277-014-2755-6. View

Zhao Z, Qin L, Li S . miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. Tumour Biol. 2015; 37(4):5551-60. DOI: 10.1007/s13277-015-4425-8. View

Nadal E, Zhong J, Lin J, Reddy R, Ramnath N, Orringer M . A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 2014; 20(12):3107-17. DOI: 10.1158/1078-0432.CCR-13-3348. View

Luzi E, Marini F, Tognarini I, Galli G, Falchetti A, Brandi M . The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. Nucleic Acid Ther. 2012; 22(2):103-8. DOI: 10.1089/nat.2012.0344. View

Nishimura M, Jung E, Shah M, Lu C, Spizzo R, Shimizu M . Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013; 3(11):1302-15. PMC: 3855315. DOI: 10.1158/2159-8290.CD-13-0159. View

Yang T, Thakur A, Chen T, Yang L, Lei G, Liang Y . MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 2015; 36(6):4357-65. DOI: 10.1007/s13277-015-3075-1. View

Kang W, Tong J, Lung R, Dong Y, Zhao J, Liang Q . Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer. 2015; 14:52. PMC: 4342823. DOI: 10.1186/s12943-015-0323-3. View

10.

Paraskevopoulou M, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas T . DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 2012; 41(Database issue):D239-45. PMC: 3531175. DOI: 10.1093/nar/gks1246. View

11.

Lycoudi A, Mavreli D, Mavrou A, Papantoniou N, Kolialexi A . miRNAs in pregnancy-related complications. Expert Rev Mol Diagn. 2015; 15(8):999-1010. DOI: 10.1586/14737159.2015.1053468. View

12.

Birks D, Barton V, Donson A, Handler M, Vibhakar R, Foreman N . Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2010; 56(2):211-6. DOI: 10.1002/pbc.22723. View

13.

Mishra P, Song B, Mishra P, Wang Y, Humeniuk R, Banerjee D . MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One. 2009; 4(12):e8445. PMC: 2794546. DOI: 10.1371/journal.pone.0008445. View

14.

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

15.

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

16.

Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi M . The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit". PLoS One. 2012; 7(6):e39767. PMC: 3384621. DOI: 10.1371/journal.pone.0039767. View

17.

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn S . Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2012; 351(1):85-98. DOI: 10.1007/s00441-012-1514-5. View

18.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

19.

Costa F, Bischof J, Vanin E, Lulla R, Wang M, Sredni S . Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011; 6(10):e25114. PMC: 3203863. DOI: 10.1371/journal.pone.0025114. View

20.

Arunachalam G, Upadhyay R, Ding H, Triggle C . MicroRNA Signature and Cardiovascular Dysfunction. J Cardiovasc Pharmacol. 2014; 65(5):419-29. DOI: 10.1097/FJC.0000000000000178. View